Literature DB >> 8496600

Use of the most JH-proximal human Ig H chain V region gene, VH6, in the expressed immune repertoire.

W S Varade1, E Marin, A M Kittelberger, R A Insel.   

Abstract

VH6, the most 3' human H chain V region gene, is preferentially expressed in the preimmune repertoire of the developing human fetus. To determine whether VH6 contributes to the immune repertoire, we amplified and sequenced from human spleen RNA VH6 rearrangements that were isotype-switched to IgG. Eighteen distinct in-frame VH6 clones were sequenced. Definitive assignment to C gamma 1 could be made in the majority of clones, and all had undergone extensive somatic hypermutation in the V region with an average of 14 (range, 2 to 25) mutations/281 bp in the VH6 segment. The overall frequency of somatic mutation was 5.2% of the total nucleotides sequenced. Replacement somatic mutations were targeted to the complementarity determining region, and the complementarity determining region had higher replacement to silent mutation ratios, consistent with antigenic selection. Silent somatic mutations were also significantly more frequent in the complementarity determining region compared to the framework region. Five clones were derived from the same VH6Dxp'1JH6 rearrangement, each containing unique and shared mutations. All DH segments used by independently arising clones were unique, and all DH reading frames were seen. N segments were lacking at either the 5'DH-JH junction or the 3'DH-JH junction in 7 of 13 independent rearrangements. DH-DH recombinations were frequently observed, and there was biased usage of JH3b and JH4b in the clones. The data imply that a high degree of diversity arises from use of this 3'-VH gene in the immune repertoire.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496600

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Evidence that the V kappa III gene usage is nonstochastic in both adult and newborn peripheral B cells and that peripheral CD5+ adult B cells are oligoclonal.

Authors:  J C Weber; G Blaison; T Martin; A M Knapp; J L Pasquali
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

2.  Molecular characterization of VDJ transcripts from a newborn piglet.

Authors:  J Sun; J E Butler
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

3.  Genetic plasticity of V genes under somatic hypermutation: statistical analyses using a new resampling-based methodology.

Authors:  M Oprea; T B Kepler
Journal:  Genome Res       Date:  1999-12       Impact factor: 9.043

4.  Superantigen properties of a human sialoprotein involved in gut-associated immunity.

Authors:  G J Silverman; P Roben; J P Bouvet; M Sasano
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

5.  Characterization of the zebrafish T cell receptor beta locus.

Authors:  Nathan D Meeker; Alexandra C H Smith; J Kimble Frazer; Diana F Bradley; Lynnie A Rudner; Cynthia Love; Nikolaus S Trede
Journal:  Immunogenetics       Date:  2010-01-07       Impact factor: 2.846

6.  Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.

Authors:  Robert W Maitta; Kausik Datta; Qing Chang; Robin X Luo; Bradley Witover; Krishanthi Subramaniam; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  Related IgA1 and IgG producing cells in blood and diseased mucosa in ulcerative colitis.

Authors:  V C Thoree; S J C Golby; L Boursier; M Hackett; D K Dunn-Walters; J D Sanderson; J Spencer
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

8.  Inherent properties of somatic hypermutation as revealed by human non-productive VH6 immunoglobulin rearrangements.

Authors:  W S Varade; J A Carnahan; P D Kingsley; R A Insel
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

9.  Somatic mutation of human immunoglobulin V genes in the X-linked HyperIgM syndrome.

Authors:  Y W Chu; E Marin; R Fuleihan; N Ramesh; F S Rosen; R S Geha; R A Insel
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.